HTL, pioneer and world leader in the development and production of innovative pharmaceutical grade biopolymers, announces that Montagu, a leading private equity firm, has acquired a majority stake of HTL previously held by Bridgepoint. The other minority shareholders, Naxicap and Téthys Invest, will keep their shares in the company.
“HTL embodies all the characteristics of a French industrial success and perfectly represents the kind of high-potential healthcare companies at the heart of our investment strategy. We are proud to be partnering with the company to support its development, “ said Guillaume Jabalot, Director at Montagu.
HTL embodies all the characteristics of a French industrial success and perfectly represents the kind of high-potential healthcare companies at the heart of our investment strategy.
Eric Aveillan, Chairman of Naxicap’s Management Board, continued: “Since our first investment in 2017, HTL has experienced an unprecedented growth phase, and the arrival of Montagu in the capital highlights the quality of the industrial project and its long-term R&D strategy.”
Alexandre Benais, CEO of Téthys Invest says: “We are pleased to welcome Montagu to support HTL in its continued development, in a business where a long-term shareholding makes sense, particularly in terms of industrial investment and research and development.”
Montagu’s acquisition is complemented by the appointment of Paul Navarre as Chairman. Paul Navarre is a board member and strategic advisor of several healthcare businesses today. He will bring his widely recognized international experience in the fields of medical aesthetics, ophthalmology, and rheumatology.
“It is truly an honor to put my experience at the service of HTL and its employees, whose innovative spirit and unwavering commitment transformed this company into an international leader” added Paul Navarre, the new Chairman.
It is truly an honor to put my experience at the service of HTL and its employees, whose innovative spirit and unwavering commitment transformed this company into an international leader.
Montagu’s acquisition occurs while HTL is benefiting from the international success of its innovative pharmaceutical grade biopolymer platform, which provides customized medical solutions to the world’s leading healthcare industries in therapeutic areas such as ophthalmology, rheumatology, urology, dermatology and medical aesthetics.
HTL has tripled its revenues in 10 years and has experienced a double-digit growth for several years, supported by a five-fold increase of its initial production capacity, the hiring of more than 100 new employees over the past three years, and the accelerated development of its R&D platform. With a strong international focus and a growing demand in all markets, HTL exports 75% of its production and has opened new offices in Singapore and the United States, while partnering with leading companies.
“Montagu’s investment is the symbol of the exceptional growth we have experienced over the past few years,” said Yvon Bastard, CEO of HTL. “We are very excited about the future of HTL, and we are delighted to have such a critical partner to help us execute the strategy that will take the company to the next level” added Charles Ruban, Deputy CEO of HTL.
Montagu’s investment is the symbol of the exceptional growth we have experienced over the past few years.
We are very excited about the future of HTL, and we are delighted to have such a critical partner to help us take the company to the next level.
Montagu’s involvement will enable HTL to accelerate its development strategy based on four priorities: premium product positioning, international expansion, corporate social responsibility, and innovation, by creating new types of biopolymers and chemical modifications while exploring the untapped potential of biopolymers in innovative applications such as regenerative medicine or drug delivery.